Actavis recalls pills made by Patheon

Allergan ($AGN), which this month completed the sale of its Actavis generics unit to Teva ($TEVA), is still cleaning up Actavis business, like the recall of tens of thousands of bottles of a diabetes drug.

According to the most recent FDA Enforcement Report, the drugmaker is recalling 5 lots, consisting of 167,152 bottles, of Glipizide, a treatment for Type 2 diabetes. The class II recall began after stability testing determined the drugs exceeded dissolution specification rates for the 10-hour testing point. The product was made for Actavis by contractor Patheon.

Actavis has had some problems with contractors recently. The Dublin-based company earlier this year voluntarily recalled 447,150 bottles, of ciprofloxacin ophthalmic solution that was manufactured by Hi-Tech Pharmacal, a unit of Lake Forest, IL-based Akorn ($AKRX).

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

Earlier this month, Allergan completed the sale of Actavis to Teva for $40 billion. Israel-based Teva, the largest generics maker in the word, also agreed to buy Actavis U.S. distribution unit, Anda, for another $500 million. With the deal, Teva CEO Erez Vigodman has pledged to increase the drug company’s revenue by as much as 40% by 2019.

- access the recall here  

Related Articles: 
Akorn's Hi-Tech is the source of large Actavis recall  
Allergan’s Actavis recalls nearly 600,000 bottles of ADHD drug
Teva wants Allergan's distribution biz now that $40B drug deal has closed


Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.